Moreover, in the same report, the association of STK11 mutation with worse clinical outcome was also confirmed among the PD-L1 positive subgroup of KRAS/STK11 mutant NSCLC patients treated with ICIs. Here, KRAS is linked to non-small cell lung carcinoma.